Mehdi Gasmi, Ph.D. is Adverum’s president and chief scientific officer. He joined the Company in 2013 and is responsible for the development of Adverum’s gene therapy candidates, including research, preclinical testing, CMC activities and Regulatory Affairs. A gene therapy veteran, Dr. Gasmi has worked in the field since 1996 at various academic institutions, including City of Hope and the University of California, San Diego, and at gene therapy companies, including Chiron, Cell Genesys, Ceregene and Genethon. Dr. Gasmi is the inventor of various technologies related to the manufacturing and clinical applications of recombinant AAV and lentiviral vectors. He received a M.S. and Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France.